CD38 and myeloproliferative disorder: In contrast, no statistically significant difference was observed when comparing patients with JAK2 V617F− MPN or normal CD34+/CD38− stem cells, although some patients with JAK2 V617F− MPN showed higher pSTAT5 levels than normal controls.